Linagliptina Stada

Linagliptin, the active ingredient in Linagliptina Stada, is a DPP-4 inhibitor presented as an oral dosage form for oral use. It is used to improve glycemic control in adults with type 2 diabetes mellitus.

GNH USA supplies Linagliptina Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linagliptin is indicated for the management of type 2 diabetes mellitus, a chronic metabolic disorder characterized by insulin resistance and impaired insulin secretion.

- Type 2 diabetes mellitus: improves overall glycemic control as monotherapy or in combination with other antidiabetic agents. - Combination with metformin: provides additional HbA1c reduction in patients whose glucose targets are not met with metformin alone. - Patients with renal impairment: can be used without dose adjustment because the drug is eliminated primarily via the bile.

Common Side Effects: - Nasopharyngitis: mild inflammation of the upper airway. - Headache: transient and usually mild. - Upper respiratory tract infection: symptoms of cough and congestion. - Dizziness: occasional light‑headed sensation. - Gastrointestinal discomfort: includes nausea or abdominal pain.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions: such as angioedema or anaphylaxis. - Hepatic injury: elevated liver enzymes or jaundice. - Severe skin reactions: including Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Linagliptin should be used with clinical vigilance and appropriate patient counseling. - Monitor renal function: assess kidney status even though dose adjustment is not required. - Assess hepatic function: use with caution in patients with liver disease. - Watch for signs of pancreatitis: discontinue if severe abdominal pain occurs. - Evaluate cardiovascular risk: consider in patients with established heart disease. - Store at room temperature: keep in the original container, protect from moisture and light.

Linagliptin may interact with several concomitant medicines; clinical assessment is advised.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may markedly reduce linagliptin exposure and efficacy. - Co‑administration with other DPP‑4 inhibitors: increases risk of hypoglycaemia. - Use with insulin or sulfonylureas: may potentiate hypoglycaemic events.

Moderate Interactions (Monitor Closely):\n- ACE inhibitors: possible additive risk of hypotension. - Diuretics: monitor fluid and electrolyte balance. - NSAIDs: may affect renal function, especially in susceptible patients.